PROBIOTICS - A PROBABLE THERAPEUTIC AGENT FOR SPONDYLOARTHROPATHY.

Q4 Medicine

International Journal of Probiotics and Prebiotics Pub Date : 2017-01-01 Epub Date: 2017-08-21

Nandini Singh, Hariom Yadav, Francesco Marotta, Vinod Singh

{"title":"PROBIOTICS - A PROBABLE THERAPEUTIC AGENT FOR SPONDYLOARTHROPATHY.","authors":"Nandini Singh, Hariom Yadav, Francesco Marotta, Vinod Singh","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Spondyloarthropathy (SpA) or spondyloarthrosis refers to any joint disease of the vertebral column. Among the entities of SpA, ankylosing spondylitis has drawn the attention of some researchers, because of its specific mechanism of disease progression. It has been studied earlier that its progression is due to the presence of HLA (human leukocyte antigen) - B27. It shows molecular similarity and immunological cross-reactivity with some of the gut microbiome. Since SpA could be treated or its symptoms could be lessen by medications, but medications itself show many side effects and other complications. Probiotic- being the natural product has been found to be effective against many SpA entities, including Ankylosing Spondylitis. It alters gut microflora somehow in such a way that it helps in reducing the predisposition of any factor to SpA. Here we consider the complex relationship between SpA pathogenesis and gut microbes; with discussion that how use of probiotics as an alternative drug therapy may treat or reduce the progression of SpA, which could be a better future target to treat SpA entities.</p>","PeriodicalId":53704,"journal":{"name":"International Journal of Probiotics and Prebiotics","volume":"12 2","pages":"57-68"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474668/pdf/nihms-991537.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Probiotics and Prebiotics","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/8/21 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Spondyloarthropathy (SpA) or spondyloarthrosis refers to any joint disease of the vertebral column. Among the entities of SpA, ankylosing spondylitis has drawn the attention of some researchers, because of its specific mechanism of disease progression. It has been studied earlier that its progression is due to the presence of HLA (human leukocyte antigen) - B27. It shows molecular similarity and immunological cross-reactivity with some of the gut microbiome. Since SpA could be treated or its symptoms could be lessen by medications, but medications itself show many side effects and other complications. Probiotic- being the natural product has been found to be effective against many SpA entities, including Ankylosing Spondylitis. It alters gut microflora somehow in such a way that it helps in reducing the predisposition of any factor to SpA. Here we consider the complex relationship between SpA pathogenesis and gut microbes; with discussion that how use of probiotics as an alternative drug therapy may treat or reduce the progression of SpA, which could be a better future target to treat SpA entities.

本刊更多论文

益生菌-脊椎关节病的可能治疗剂。

脊椎关节病（Spondyloarthropathy, SpA）或脊椎关节病是指脊柱的任何关节疾病。在SpA实体中，强直性脊柱炎因其特定的疾病进展机制而引起了一些研究者的关注。早期研究表明，其进展是由于HLA（人类白细胞抗原）- B27的存在。它与一些肠道微生物组具有分子相似性和免疫交叉反应性。由于SpA可以通过药物治疗或减轻其症状，但药物本身有许多副作用和其他并发症。益生菌作为天然产品已被发现对许多SpA实体有效，包括强直性脊柱炎。它以某种方式改变肠道菌群，从而有助于减少任何因素对SpA的易感性。在这里，我们考虑SpA发病机制与肠道微生物之间的复杂关系；并讨论了使用益生菌作为替代药物治疗如何治疗或减少SpA的进展，这可能是未来治疗SpA实体的更好靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Probiotics and Prebiotics Nursing-Nutrition and Dietetics

CiteScore

1.20

自引率

0.00%

发文量

期刊介绍： The International journal of Probiotics & Prebiotics publishes on online only in an open access format. This is a broad based international, interdisciplinary peer reviewed scientific journal for critical evaluation of research on prebiotics, probiotics and synbiotics. The major goal of this journal is to provide unbiased scientific data to students, researchers, healthcare providers, and the decision makers in the nutraceutical industry to help make informed choices about prebiotics, probiotics and synbiotics. To this end, the journal will publish original research articles and two types of review articles. First, we will publish a review of preclinical research data coming largely from animal, cell culture and other experimental models. Such data will provide basis for future product development and/or human research initiatives. Second, we will publish a critical evaluation of current human experimental data to help deliver products with medically proven use.